CN113318003A - Jellyfish polypeptide and application thereof - Google Patents
Jellyfish polypeptide and application thereof Download PDFInfo
- Publication number
- CN113318003A CN113318003A CN202110381493.8A CN202110381493A CN113318003A CN 113318003 A CN113318003 A CN 113318003A CN 202110381493 A CN202110381493 A CN 202110381493A CN 113318003 A CN113318003 A CN 113318003A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- jellyfish
- molecular weight
- skin
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of marine organism utilization, in particular to jellyfish polypeptide and application thereof. The jellyfish polypeptide is zymolyte of an umbrella part or a mouth and wrist part of desalted jellyfish, the molecular weight is less than 5000Da, wherein the molecular weight M is less than 1000Da and accounts for 20-35% of the peptide weight, the molecular weight M is less than 1000Da and accounts for 55-70% of the peptide weight, the molecular weight M is less than 3000Da and accounts for less than 10% of the peptide weight, the molecular weight M is less than 3000Da and accounts for 10-15% of the total amino acid. The preparation method of the jellyfish polypeptide preparation comprises the following steps: the jellyfish polypeptide is dissolved in deionized water, and the concentration is 0.02-10 mg/mL. The jellyfish polypeptide is utilized to respectively promote the synthesis of HDFn I collagen of human skin fibroblasts, prepare skin care products such as skin barrier repair agents, inflammatory factor inhibitors and the like, expand the application range of the jellyfish polypeptide, and open up a new way for applying marine bioactive substances to the fields of skin care products and skin disease treatment. In addition, the invention provides an effective strategy for dealing with the flourishing jellyfishes from the aspect of resource utilization, improves the additional value of jellyfish resources and prolongs the industrial chain.
Description
Technical Field
The invention relates to the technical field of marine organism utilization, in particular to jellyfish polypeptide and application thereof.
Background
The skin barrier is the first physiological barrier of human body, is composed of horny layer, lipid and the like, can resist the entry of external bacteria, viruses, irritants and the like, wherein the type I collagen is a special triple helix structure formed by three chains which are mutually wound, is an important component of human skin, and has important functions of maintaining skin tension and keeping skin young state. The skin barrier damage not only causes skin wrinkles and aging, but also causes dermatitis, eczema, psoriasis, viral dermatosis and the like, and the reduction of the content of the type I collagen in the skin also causes the degenerative change of the tissue structure and physiological function of the skin, which is manifested as skin relaxation, dryness and the like. Therefore, the skin barrier repair, the prevention of skin inflammation and the promotion of the synthesis of type I collagen in skin cells have important functions on maintaining the young state of the skin and preventing skin diseases.
At present, researches on active substances for repairing skin barrier damage mainly focus on plant extracts such as grape seed procyanidin and liquorice extract, and compositions mainly comprising various plant components in the cosmetic industry are mainly used for repairing skin barriers such as wild soybean extract, polygonum cuspidatum root extract and garden balsam stem extract. However, no research report on the application of marine bioactive substances in repairing skin barrier damage is found at present. Secondly, in order to relieve skin inflammation, some cosmetics contain illicit hormonal components. The long-term use of cosmetics containing hormones seriously affects the physiological functions of the skin, thins the stratum corneum of the skin, increases the sensitivity of the skin, and even causes hormone-dependent dermatitis. Similarly, other resources (such as marine organisms) are rarely studied for their application in this regard, and therefore screening anti-inflammatory active substances from marine organisms for use in cosmetics has an important role in improving the safety and quality of cosmetics. In addition, the type I collagen is formed by three chains intertwining with each other to form a special triple-helix structure, and the content of the type I collagen in the skin is reduced along with the increase of the age, so that the tissue structure and the physiological function of the skin are degenerated, and the skin is shown to be loose, dry and the like. The screening of bioactive substances which can promote the synthesis of the type I collagen of skin cells has important significance for relieving skin aging.
The jellyfish belongs to coelenterate animals and is rich in resources. Due to high water content, only a few of jellyfishes are used as food after being salted, the additional value is low, and the waste of resources is caused. Jellyfish contains abundant protein, and the protein in jellyfish is converted into polypeptide by utilizing an enzymolysis technology, which is the key for processing and high-value utilization of jellyfish resources. In addition, the study on the jellyfish peptide at the present stage mainly focuses on the jellyfish collagen peptide, namely, the jellyfish collagen peptide is prepared by extracting the jellyfish collagen by acid, alkali, hot water or enzymatic method, and then carrying out enzymolysis on the collagen by using protease. During extraction of aequorin, a large amount of acid-soluble or alkali-soluble protein is discarded, resulting in low utilization of aequorin. The method converts protein in jellyfish into polypeptide by utilizing an enzymolysis technology, widens the application field of jellyfish resources, and is the key for processing and high-value utilization of jellyfish resources.
Although there are some related arts using marine organisms, such as a preparation method of jellyfish collagen emulsion disclosed in application No. 201710451233.7, and the use of jellyfish extract disclosed in the patent publication No. CN107625789B, the disclosed data are relatively single objects of marine organisms, specific application components, and the effects achieved. Therefore, the application adopts the zymolyte of the desalted jellyfish as a research object to research the application of the zymolyte of the desalted jellyfish as an inflammatory factor inhibitor, a skin barrier damage repairing agent, an I type collagen synthesis preparation and the like.
Disclosure of Invention
In view of the above technical problems, the first aspect of the present invention provides an jellyfish polypeptide, which is a zymolyte of an umbrella part or a mouth-wrist part of a desalted jellyfish, and has a molecular weight of not more than 5000 daltons.
As a preferred technical scheme of the present invention, the zymolyte comprises a high molecular weight polypeptide, a medium molecular weight polypeptide and a low molecular weight polypeptide; the molecular weight of the high molecular weight polypeptide is not less than 3000 daltons; the low molecular weight polypeptide has a molecular weight of no more than 1000 daltons; the molecular weight of the medium molecular weight polypeptide is 1000-3000 daltons.
As a preferred technical scheme of the invention, the molecular weight of the high molecular weight polypeptide is 3000-5000 daltons.
As a preferred technical scheme, the content of the low molecular weight polypeptide is 20-35 wt%; the content of the medium molecular weight polypeptide is 55-70 wt%; the content of the high molecular weight polypeptide is not higher than 10 wt%.
As a preferred technical solution of the present invention, the zymolyte comprises glycine; the glycine content is 10-15 wt%.
In a second aspect, the invention provides the use of jellyfish polypeptide as described above in the preparation of skin care products.
As a preferable technical scheme of the invention, the preparation method of the skin care product comprises the following steps: preparing the jellyfish polypeptide into an aqueous solution with the concentration of 0.02-10mg/mL by using deionized water, and then filtering the aqueous solution by using a microporous filter membrane with the pore diameter of not more than 0.25 mu m.
In a preferred embodiment of the present invention, the skin care product is an inflammatory factor inhibitor.
As a preferred technical scheme, the skin care product is a skin barrier repairing agent.
As a preferable technical scheme, the skin care product is a preparation for promoting synthesis of type I collagen of skin cells.
Has the advantages that: in the invention, the zymolyte (jellyfish polypeptide) of the umbrella part or the oral wrist part of the desalted jellyfish is researched, and experimental analysis shows that the jellyfish polypeptide consisting of different polypeptide components has excellent effect when being applied to skin care products. The jellyfish polypeptide is utilized to respectively promote the synthesis of HDFn I collagen of human skin fibroblasts, prepare skin care products such as skin barrier repair agents, inflammatory factor inhibitors and the like, expand the application range of the jellyfish polypeptide, and open up a new way for applying marine bioactive substances to the fields of skin care products and skin disease treatment. In addition, the invention provides an effective strategy for dealing with the flourishing jellyfishes from the aspect of resource utilization, improves the additional value of jellyfish resources and prolongs the industrial chain.
Drawings
FIG. 1 is a graph showing the survival rates of human skin fibroblasts HDFn and human skin keratinocytes HaCaT under the effect of jellyfish polypeptides of different concentrations according to the present invention.
FIG. 2 shows the IL-1 α content (p <0.01, # to negative control, p <0.05, # to negative control, p <0.01) of various concentrations of jellyfish polypeptide according to the present invention.
FIG. 3 ET of epidermal model with jellyfish polypeptide of different concentrations in the examples of the present invention50Figure (a).
FIG. 4 is a graph of HDFn type I collagen of human skin fibroblasts in response to various concentrations of jellyfish polypeptides in an embodiment of the invention (. about.. about.0.01,. about.0.05,. about.0.01,. about.0.05).
Detailed Description
The technical features of the technical solutions provided by the present invention will be further clearly and completely described below with reference to the specific embodiments, and it should be apparent that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The words "preferred", "preferably", "more preferred", and the like, in the present invention, refer to embodiments of the invention that may provide certain benefits, under certain circumstances. However, other embodiments may be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, nor is it intended to exclude other embodiments from the scope of the invention.
It should be understood that other than in any operating examples, or where otherwise indicated, all numbers expressing, for example, quantities of ingredients used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
The first aspect of the invention provides an jellyfish polypeptide, which is a zymolyte of an umbrella part or a mouth and wrist part of desalted jellyfish, and has a molecular weight of not more than 5000 daltons.
The method for enzymolysis of the umbrella part or the wrist part of the desalted jellyfish is not particularly limited, and the method can be prepared by enzymolysis according to the conventional method in the field, for example, the umbrella part or the wrist part of the desalted jellyfish is dissolved in deionized water, corresponding enzyme is added, and then the conditions such as the pH value, the temperature and the like of the system are adjusted for hydrolysis. Or may be obtained from commercial sources.
The applicant finds that when the enzymolysis of the umbrella part or the wrist part of desalted jellyfish is used for preparations such as an inflammatory factor inhibitor, a skin barrier repair agent and a preparation for promoting the synthesis of type I collagen of skin cells, the molecular weight of the polypeptide in the preparations cannot be too high, otherwise, the promotion speed of the synthesis of the type I collagen by the preparations is seriously influenced, the skin barrier repair effect is influenced, and the inhibition effect of inflammatory factors is also seriously influenced. It is possible that when the molecular weight of the polypeptide in the enzymatic hydrolysate is too high, the permeation rate of the polypeptide into the skin is reduced due to more physical entanglement points in the molecular structure of the polypeptide with high molecular weight, and the migration and absorption rate in the epidermis are influenced. When the molecular weight of the adopted polypeptide is lower than 5000 daltons, the active ingredients in the preparation can be rapidly absorbed by skin cells, and keratinocyte HaCaT and fibroblast HDFn are activated, so that the immunity of the skin to external stimulation is enhanced.
In some embodiments, the substrate comprises a high molecular weight polypeptide, a medium molecular weight polypeptide, and a low molecular weight polypeptide; the molecular weight of the high molecular weight polypeptide is not less than 3000 daltons; the low molecular weight polypeptide has a molecular weight of no more than 1000 daltons; the molecular weight of the medium molecular weight polypeptide is 1000-3000 daltons.
In some embodiments, the high molecular weight polypeptide has a molecular weight of 3000 to 5000 daltons.
In some embodiments, the low molecular weight polypeptide is present in an amount of 20 to 35 wt%; the content of the medium molecular weight polypeptide is 55-70 wt%; the content of the high molecular weight polypeptide is not higher than 10 wt%.
The method for measuring the molecular weight and the polypeptide content of the zymolyte of the umbrella part or the mouth and wrist part of the desalted jellyfish is not particularly limited in the invention, and the zymolyte can be obtained by testing according to the conventional means in the field, such as electrophoresis, high performance liquid chromatography and the like.
In the process of researching jellyfish polypeptides, the inventor finds that the regulation and control of the molecular weight and the content of polypeptides with different molecular weights can greatly accelerate the protection and proliferation and differentiation promotion of the obtained preparation on keratinocytes HaCaT and fibroblasts HDFn, and further improves the inhibition effect of the obtained preparation on inflammatory factors, the skin repair effect and the promotion effect of skin cell type I collagen synthesis. The inventor speculates that the preparation is probably because the small molecular weight polypeptide is rapidly absorbed and is contacted with keratinocytes (HaCaT) and fibroblasts (HDFn) in the skin to regulate the microscopic state of the skin when the preparation is used after the preparation is compounded by the polypeptides with different molecular weights and different contents, and the medium molecular weight polypeptide and the high molecular weight polypeptide are gradually absorbed by the skin cells to gradually improve the microscopic environment of the skin, so that the phenomenon that the key cells are directly exposed in high-concentration preparation components to cause cytotoxicosis is avoided. Meanwhile, after the polypeptides with different molecular weights are combined, the stability of some polypeptides with low molecular weight and high activity can be improved under the interaction between chain segments with different lengths in the polypeptides, so that the comprehensive effect of the preparation is improved.
In some embodiments, glycine is included in the substrate; the glycine content is 10-15 wt%. The applicant finds that the glycine content in the zymolyte has certain influence on reducing the toxicity of the jellyfish polypeptide to keratinocytes (HaCaT) and fibroblasts (HDFn), and the glycine content in the zymolyte is controlled to help reduce the toxicity of the jellyfish polypeptide to the two cells, so that the content of the active ingredients of the jellyfish polypeptide in the jellyfish polypeptide preparation is increased, and the skin barrier repair effect of the preparation and the inflammatory factor inhibition effect of the preparation are improved. It is possible that glycine in the system can improve the interaction between polypeptides of different molecular weights and enhance the synergistic interaction between the components in the system, thereby achieving the above-described effects.
In a second aspect, the invention provides the use of jellyfish polypeptide as described above in the preparation of skin care products.
In some embodiments, the method of making the skin care article comprises the steps of: preparing the jellyfish polypeptide into an aqueous solution with the concentration of 0.02-10mg/mL by using deionized water, and then filtering the aqueous solution by using a microporous filter membrane with the pore diameter of not more than 0.25 mu m. Preferably, the membrane is prepared by filtration through a 0.22 μm microporous membrane.
The safe dose of jellyfish polypeptide was determined by determining the toxicity of jellyfish polypeptide to keratinocytes HaCaT and fibroblasts HDFn. Skin keratinocytes and fibroblasts play an important role in protecting skin from external invasion and tissue injury repair processes, so that toxicity of jellyfish polypeptide on the keratinocytes HaCaT and the fibroblasts HDFn is determined to determine the safe dose of the jellyfish polypeptide. The experimental procedure was as follows: collecting human skin fibroblast HDFn or human keratinocyte HaCaT with logarithmic growth cycle, and inoculating at 8000 cells/wellTo 96-well plates, each well contained 100. mu.l of culture medium. In an incubator (37 ℃, 5% CO)295% RH), the medium was aspirated, the cells were washed twice with PBS buffer, different concentrations (0.02mg/mL, 0.04mg/mL, 0.08mg/mL, 0.16mg/mL, 0.32mg/mL, 0.63mg/mL, 1.25mg/mL, 2.5mg/mL, 5mg/mL, 10mg/mL, 15mg/mL) of jellyfish polypeptide were added at 100. mu.l per well, untreated cells were used as negative controls, only the wells of cell culture were added as blank wells, and 3 replicate wells were set for each group. After adding the drug, the mixture is cultured in an incubator (37 ℃, 5% CO)295% RH) for 48h, then carrying out CCK-8 cytotoxicity test, and measuring the absorbance A value at 450 nm. The effect of jellyfish polypeptide on the survival rate of human dermal fibroblasts HDFn or human keratinocytes HaCaT was calculated according to the following formula to determine the safe dose range of jellyfish polypeptide.
The survival rates of human skin fibroblast HDFn and human keratinocyte HaCaT under different concentrations are shown in figure 1, and the safe dosage of jellyfish polypeptide to two skin cells is 0.02-10mg/mL according to figure 1 and the growth state of the cells.
Wherein: the preparation method of the jellyfish polypeptide comprises the following steps: dissolving 150mg of jellyfish polypeptide in 10mL of deionized water to prepare 15mg/mL jellyfish polypeptide solution; then, 15mg/mL of jellyfish polypeptide was diluted with deionized water to prepare jellyfish polypeptide solutions having concentrations of 0.02mg/mL, 0.04mg/mL, 0.08mg/mL, 0.16mg/mL, 0.32mg/mL, 0.63mg/mL, 1.25mg/mL, 2.5mg/mL, 5mg/mL, 10mg/mL, and 15mg/mL, respectively.
Inflammation factor inhibitor
In some embodiments, the skin care article is an inflammatory factor inhibitor. The jellyfish polypeptide inflammatory factor inhibitor can be used independently, and can also be used as an effective component to be combined with other substances. The jellyfish polypeptide can be used as an inflammatory factor inhibitor and can be applied to the fields of cosmetics and medicines.
Using three-dimensional skin modelsType evaluation of the efficacy of jellyfish polypeptides as inhibitors of inflammatory factors can be made with reference to the following references: zhanyanyun, Lirong Zhi, Jiangshan, He Qing, Weilina, Luyongbao, Xuliming, three-dimensional epidermis model
The research and development of reference products and the journal of drug analysis, 2019,39(12): 2117-: 1) and (3) recovering the epidermis model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to EpiRecovery medium and the culture was continued in an incubator (37 ℃ C., 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mL EpiGrowth medium per well, and the prepared jellyfish polypeptide was slowly dropped on the epidermal model surface by a pipette to administer at 25 μ L per dose setting 3 replicates per dose, no administration was given to the negative control group, and 0.05% dexamethasone was used as a positive control at 25 μ L. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab and placed in a 24-well plate containing 0.9mL of EpiGrowth medium per well. 3) And (3) detecting inflammatory factors: slowly dropping 0.2% SLS on the surface of epidermis model with a pipette to administer 25 μ L, placing 24-well culture plate in incubator (37 deg.C, 5% CO)295% RH), transferring the culture solution to a centrifuge tube, and detecting the content of the inflammatory factor IL-1 alpha according to the IL-1 alpha ELISA kit instruction.
Example 1
1) Resurgence of the epidermis model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9mL EpiRecovery and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mLEPIGrowth medium per well, and 0.02mg/mL of jellyfish polypeptide (where M is<1000Da accounting for 33% and 1000Da<M<3000Da in 59%, 3000Da<M<5000Da accounting for 8 percent and glycine accounting for 11 percent of total amino acids) is slowly dripped on the surface of the epidermis model by a pipette for administration, the administration amount is 25 mu L, each dose is set to 3 parallel experiments, a negative control group is not administered, and 0.05 percent of dexamethasone is used as a positive control, and the administration amount is 25 mu L. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab and placed in a 24-well plate containing 0.9ml of LEPIGrowth medium per well. 3) Inflammatory factor detection: slowly dropping 0.2% SLS on the surface of epidermis model with a pipette to administer 25 μ L, placing 24-well culture plate in incubator (37 deg.C, 5% CO)295% RH), transferring the culture solution to a centrifuge tube, and detecting the content of the inflammatory factor IL-1 alpha according to the IL-1 alpha kit instruction. The IL-1 alpha content of the positive control group (0.05% dexamethasone) is 11.21 +/-0.20 pg/mL, the IL-1 alpha content of the jellyfish polypeptide treatment group is 12.63 +/-0.20 pg/mL, and the significant difference (p is less than 0.05) is respectively realized compared with the IL-1 alpha content of the negative control group which is 13.22 +/-0.20 pg/mL, as shown in the attached figure 2.
Example 2
1) Resurgence of the epidermis model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9ml of LEPIRecovery medium and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mLEPIGrowth medium per well, and 0.63mg/mL of jellyfish polypeptide (M)<1000Da accounting for 22% and 1000Da<M<3000Da is 69%, 3000Da<M<5000Da accounting for 9 percent and glycine accounting for 13 percent of the total amino acids) is slowly dripped on the surface of the epidermis model by a pipette for administration,the dose was 25 μ L, 3 replicates per dose were set, the negative control group was not dosed, 0.05% dexamethasone was used as positive control, and the dose was 25 μ L. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab and placed in a 24-well plate containing 0.9ml of LEPIGrowth medium per well. 3) Inflammatory factor detection: slowly dropping 0.2% SLS on the surface of epidermis model with a pipette to administer 25 μ L, placing 24-well culture plate in incubator (37 deg.C, 5% CO)295% RH), transferring the culture solution to a centrifuge tube, and detecting the content of the inflammatory factor IL-1 alpha according to the IL-1 alpha kit instruction. The IL-1 alpha content of the positive control group (0.05% dexamethasone) is 11.21 +/-0.20 pg/mL, the IL-1 alpha content of the jellyfish polypeptide treatment group is 12.35 +/-0.12 pg/mL, and the significant difference (p is less than 0.01) is respectively realized compared with the IL-1 alpha content of the negative control group which is 13.22 +/-0.20 pg/mL, as shown in the attached figure 2.
Example 3
1) Resurgence of the epidermis model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9mL EpiRecovery and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mLEPIGrowth medium per well, and 10mg/mL of jellyfish polypeptide (M)<1000Da accounting for 28% and 1000Da<M<3000Da in 65%, 3000Da<M<5000Da accounting for 7 percent and glycine accounting for 14 percent of total amino acids) is slowly dripped on the surface of the epidermis model by a pipette to be administered, the administration amount is 25 mu L, each dosage is set to 3 parallel experiments, a negative control group is not administered, and 0.05 percent dexamethasone is used as a positive control, and the administration amount is 25 mu L. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer, the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab, and the epidermis model was placed in each wellIn 24-well plates containing 0.9ml of LEPIGrowth medium. 3) Inflammatory factor detection: slowly dropping 0.2% SLS on the surface of epidermis model with a pipette to administer 25 μ L, placing 24-well culture plate in incubator (37 deg.C, 5% CO)295% RH), transferring the culture solution to a centrifuge tube, and detecting the content of the inflammatory factor IL-1 alpha according to the IL-1 alpha kit instruction. The IL-1 alpha content of the positive control group (0.05% dexamethasone) is 11.21 +/-0.20 pg/mL, the IL-1 alpha content of the jellyfish polypeptide treatment group is 11.90 +/-0.12 pg/mL, and the significant difference (p is less than 0.01) is respectively realized compared with the IL-1 alpha content of the negative control group which is 13.22 +/-0.20 pg/mL, as shown in the attached figure 2.
Skin barrier repair agent
In some embodiments, the skin care article is a skin barrier repair agent. The jellyfish polypeptide skin barrier repair agent can be used independently, and can also be used as an effective component to be combined with other substances.
The evaluation of jellyfish polypeptide skin barrier repair efficacy by using a three-dimensional epidermis model can be carried out by referring to the following documents: zhanyanyun, Lirong Zhi, Jiangshan, He Qing, Weilina, Luyongbao, Xuliming, three-dimensional epidermis model
The research and development of reference products and the journal of drug analysis, 2019,39(12): 2117-: 1) activation of the epidermal model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9ml of LEPIRecovery medium and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mL EpiGrowth medium per well, and the prepared jellyfish polypeptide was slowly dropped on the surface of the epidermal model by a pipette for administration in an amount of 25 μ L, 9 replicates per dose, and no administration was performed in the blank group. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH) for 24 hours, and thenThe epidermis model was washed 15 times with sterile phosphate buffer, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab. 3) ET50Detection (by rapid penetration, the exposure time required for tissue viability to decrease to 50% after treatment with 1% TritonX-100, i.e. ET50For evaluating the barrier function of the epidermal skin model): setting three action time points of 0 hour, 1 hour and 3 hours for each group of skin model, setting 3 epidermal skin models for each action time point, directly cleaning at the action time point of 0 hour without adding TritonX-100, respectively adding 80 mu L of 1% TritonX-100 at the action time points of 1 hour and 3 hours, after the TritonX-100 acts for a corresponding time, flushing the epidermal model with sterile phosphoric acid buffer solution for 15 times, wiping with sterile cotton stick, placing into a new 24-well plate, adding 300 mu L of 1mg/mL MTT solution, placing into an incubator (37 ℃, 5% CO, and 5 ℃), and placing into a vacuum chamber295% RH), the epidermis model was removed from the MTT solution, the remaining MTT solution was wiped off gently with a cotton swab, placed in a clean 24-well plate, 2mL of isopropanol was added to each well, after shaking for 2 hours, 200 μ L of isopropanol extract was removed from each well, the absorbance a value was measured at 570nm, and isopropanol was used as a blank control. Calculating the tissue survival rate of the epidermis model according to the following formula, taking two numerical values with the memory survival rate of about 50% in the same group, drawing by linear regression fitting, and calculating ET50The value is obtained. Test group ET50Negative control group ET50The test substance has barrier repair effect.
Example 4
1) Activation of the epidermal model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9ml of LEPIRecovery medium and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mL of EpiGrowth medium per well, and 0.02mg/mL of jellyfish polypeptide (M)<1000Da accounting for 33% and 1000Da<M<3000Da in 59%, 3000Da<M<5000Da 8%, glycine in total amino acidsContent 11%) was slowly dropped onto the surface of the epidermis model by a pipette to administer 25. mu.L of the drug, 9 replicates of each dose were set, and no drug was administered to the blank group. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer solution, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab. 3) ET50Detection (by rapid penetration, the time of drug exposure, ET, required for tissue viability to decrease to 50% after treatment with 1% TritonX-100 was determined50For evaluating the barrier function of the epidermal skin model): setting three action time points of 0 hour, 1 hour and 3 hours for each group of skin model, 3 epidermal skin models for each action time point, directly cleaning the skin models at the action time point of 0 hour, not adding TritonX-100, respectively adding 80 mu L of 1% TritonX-100 at the action time point of 1 hour and 3 hours, after the TritonX-100 acts for corresponding time, flushing the epidermal models with sterile phosphoric acid buffer solution for 15 times, wiping the skin models with a sterile cotton stick, putting the cleaned skin models into a new 24-pore plate, adding 300 mu L of 1mg/mL MTT solution, putting the skin models into an incubator (37 ℃, 5% CO2 and 95% RH) for 3 hours, taking out the epidermal models from the MTT solution, wiping the residual MTT solution with a cotton swab, putting the cleaned skin models into the 24-pore plate, adding 2mL of isopropanol into each pore, shaking the skin models for 2 hours, taking 200 mu L of isopropanol extract from each pore, and measuring the absorbance A value at 570nm, isopropanol was used as a blank. Calculating ET50The value is 12.65min, which is higher than that of the negative control group ET50The value is 6.38min, which indicates that the test substance has barrier repair effect. The results are shown in FIG. 3.
Example 5
1) Activation of the epidermal model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9ml of LEPIRecovery medium and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Administration of jellyfish polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mL of EpiGrowth medium per well, and 0.63mg/mL of jellyfish polypeptide (M)<1000Da accounting for 22% and 1000Da<M<3000Da is 69%, 3000Da<M<5000Da of 9 percent and glycine of 13 percent of total amino acids) are slowly dripped on the surface of the epidermis model by a pipette for administration, the administration amount is 25 mu L, each dose is set to 9 parallel experiments, and a blank group is not administered. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer solution, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab. 3) ET50Detection (by rapid penetration, the time of drug exposure, ET, required for tissue viability to decrease to 50% after treatment with 1% TritonX-100 was determined50For evaluating the barrier function of the epidermal skin model): setting three action time points of 0 hour, 1 hour and 3 hours for each group of skin model, setting 3 epidermal skin models for each action time point, directly cleaning at the action time point of 0 hour without adding TritonX-100, respectively adding 80 mu L of 1% TritonX-100 at the action time points of 1 hour and 3 hours, after the TritonX-100 acts for a corresponding time, flushing the epidermal model with sterile phosphoric acid buffer solution for 15 times, wiping with sterile cotton stick, placing into a new 24-well plate, adding 300 mu L of 1mg/mL MTT solution, placing into an incubator (37 ℃, 5% CO, and 5 ℃), and placing into a vacuum chamber295% RH), the epidermis model was removed from the MTT solution, the remaining MTT solution was wiped off gently with a cotton swab, placed in a clean 24-well plate, 2mL of isopropanol was added to each well, after shaking for 2 hours, 200 μ L of isopropanol extract was removed from each well, the absorbance a value was measured at 570nm, and isopropanol was used as a blank control. Calculating ET50The value is 26.81min, higher than that of the negative control group ET50The value is 6.38min, which indicates that the test substance has barrier repair effect. The results are shown in FIG. 3.
Example 6
1) Activation of the epidermal model: 0.9mL EpiRecovery medium was added to a sterile 24-well plate, the epidermal model was transferred to medium and placed in an incubator (37 ℃, 5% CO)295% RH), the epidermis model was transferred to a medium supplemented with 0.9ml of LEPIRecovery medium and continued in an incubator (37 ℃, 5% CO)295% RH) for 16-20 hours. 2) Water, waterAdministration of the parent polypeptide: the epidermal model was placed in a new 24-well plate containing 0.9mL of EpiGrowth medium per well, and 10mg/mL of jellyfish polypeptide (M)<1000Da accounting for 28% and 1000Da<M<3000Da in 65%, 3000Da<M<5000Da accounting for 7 percent and glycine accounting for 14 percent of total amino acids) is slowly dripped on the surface of the epidermis model by a pipette to be administered, the dosage is 25 mu L, each dosage is set for 9 parallel experiments, and a blank group is not administered. Placing the 24-well culture plate in an incubator (37 deg.C, 5% CO)295% RH), the epidermis model was washed 15 times with sterile phosphate buffer solution, and the residual liquid inside and outside the epidermis model was wiped off with a sterile cotton swab. 3) ET50Detection (by rapid penetration, the time of drug exposure, ET, required for tissue viability to decrease to 50% after treatment with 1% TritonX-100 was determined50For evaluating the barrier function of the epidermal skin model): setting three action time points of 0 hour, 1 hour and 3 hours for each group of skin model, setting 3 epidermal skin models for each action time point, directly cleaning at the action time point of 0 hour without adding TritonX-100, respectively adding 80 mu L of 1% TritonX-100 at the action time points of 1 hour and 3 hours, after the TritonX-100 acts for a corresponding time, flushing the epidermal model with sterile phosphoric acid buffer solution for 15 times, wiping with sterile cotton stick, placing into a new 24-well plate, adding 300 mu L of 1mg/mL MTT solution, placing into an incubator (37 ℃, 5% CO, and 5 ℃), and placing into a vacuum chamber295% RH), the epidermis model was removed from the MTT solution, the remaining MTT solution was wiped off gently with a cotton swab, placed in a clean 24-well plate, 2mL of isopropanol was added to each well, after shaking for 2 hours, 200 μ L of isopropanol extract was removed from each well, the absorbance a value was measured at 570nm, and isopropanol was used as a blank control. Calculating ET50The value is 30.21min, higher than that of negative control group ET50The value is 6.38min, which indicates that the test substance has barrier repair effect. The results are shown in FIG. 3.
Preparation for promoting synthesis of type I collagen in skin cells
In some embodiments, the skin care article is a formulation that promotes collagen type i synthesis in skin cells. The jellyfish polypeptide preparation for promoting skin cell type I collagen synthesis can be used independently, and can also be used as an effective component to be combined with other substances.
The experimental method for promoting the synthesis of the skin cell type I collagen by the jellyfish polypeptide comprises the following steps: 1) dissolving jellyfish polypeptide with deionized water, and filtering with 0.22 μm microporous membrane. 2) Collecting human skin fibroblasts of logarithmic growth cycle HDFn at a cell density of 105One/well was inoculated into 12-well plates in an incubator (37 ℃ C., 5% CO)295% RH), 4 replicate wells per group were set with a safe dose of jellyfish polypeptide, 30 μmol/L ascorbic acid as a positive control and untreated cells as a negative control. Adding jellyfish polypeptide, culturing in incubator (37 deg.C, 5% CO)295% RH) for 48 hours, and then the culture broth was collected. The detection of the type I collagen content in the culture solution was performed according to the instructions of the ColI ELISA kit.
Example 7
Human skin fibroblasts HDFn of logarithmic growth cycle were collected at a cell density of 105One/well was inoculated into 12-well plates in an incubator (37 ℃ C., 5% CO)295% RH) for 24 hours, 0.02mg/mL of jellyfish polypeptide (M)<1000Da accounting for 33% and 1000Da<M<3000Da in 59%, 3000Da<M<5000Da 8%, glycine 11% of total amino acids), 30. mu. mol/L ascorbic acid as a positive control and untreated cells as a negative control, 4 replicate wells per group. Adding jellyfish polypeptide, culturing in incubator (37 deg.C, 5% CO)295% RH) for 48 hours, and then the culture broth was collected. According to the steps of the ColI ELISA kit specification, a standard curve of the concentration and the light absorption value of the type I collagen is prepared, the content of the type I collagen in the culture solution is detected, and according to the standard curve, the content of the type I collagen is 77.81 +/-7.65 ng/mL, which is obviously higher than that of the type I collagen of a positive control group (7.67 +/-0.63 ng/mL) and that of the type I collagen of a negative control group (9.91 +/-0.54 ng/mL) is obtained, as shown in the attached figure 4.
Example 8
Collection of human skin fibroblasts with logarithmic growth cycleHDFn of 10 cell density5One/well was inoculated into 12-well plates in an incubator (37 ℃ C., 5% CO)295% RH) was added to the culture medium for 24 hours, and 0.63mg/mL of jellyfish polypeptide (M)<1000Da accounting for 22% and 1000Da<M<3000Da is 69%, 3000Da<M<5000Da of 9 percent and glycine of 13 percent of total amino acids), and each group was provided with 4 replicate wells with 30. mu. mol/L ascorbic acid as a positive control and untreated cells as a negative control. Adding jellyfish polypeptide, culturing in incubator (37 deg.C, 5% CO)295% RH) for 48 hours, and then the culture broth was collected. According to the steps of the ColI ELISA kit specification, a standard curve of the concentration and the light absorption value of the type I collagen is prepared, the content of the type I collagen in the culture solution is detected, and according to the standard curve, the content of the type I collagen is 51.82 +/-4.63 ng/mL, which is obviously higher than the content of the type I collagen in a positive control group (7.67 +/-0.63 ng/mL) and the content of the type I collagen in a negative control group (9.91 +/-0.54 ng/mL) is obtained, as shown in the attached figure 4.
Example 9
Human skin fibroblasts HDFn of logarithmic growth cycle were collected at a cell density of 105One/well was inoculated into 12-well plates in an incubator (37 ℃ C., 5% CO)295% RH) for 24 hours, 10mg/mL of jellyfish polypeptide (M)<1000Da accounting for 28% and 1000Da<M<3000Da in 65%, 3000Da<M<5000Da of 7 percent, glycine of 14 percent of the total amino acids), and 30 mu mol/L ascorbic acid as a positive control and untreated cells as a negative control, wherein each group is provided with 4 duplicate wells. Adding jellyfish polypeptide, culturing in incubator (37 deg.C, 5% CO)295% RH) for 48 hours, and then the culture broth was collected. According to the steps of the ColI ELISA kit specification, a standard curve of the concentration and the light absorption value of the type I collagen is prepared, the content of the type I collagen in the culture solution is detected, and according to the standard curve, the content of the type I collagen is 60.43 +/-7.54 ng/mL, which is obviously higher than that of a positive control group (7.67 +/-0.63 ng/mL) and that of a negative control group (9.91 +/-0.54 ng/mL) is obtained, as shown in the attached figure 4.
Finally, it should be understood that the above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The jellyfish polypeptide is a zymolyte of an umbrella part or a mouth and wrist part of desalted jellyfish, and the molecular weight of the jellyfish polypeptide is not higher than 5000 daltons.
2. The jellyfish polypeptide of claim 1, wherein the substrate comprises a high molecular weight polypeptide, a medium molecular weight polypeptide, and a low molecular weight polypeptide; the molecular weight of the high molecular weight polypeptide is not less than 3000 daltons; the low molecular weight polypeptide has a molecular weight of no more than 1000 daltons; the molecular weight of the medium molecular weight polypeptide is 1000-3000 daltons.
3. The jellyfish polypeptide of claim 2, wherein the high molecular weight polypeptide has a molecular weight of 3000 to 5000 daltons.
4. The jellyfish polypeptide of claim 2, wherein the low molecular weight polypeptide is present in an amount of 20 to 35 wt%; the content of the medium molecular weight polypeptide is 55-70 wt%; the content of the high molecular weight polypeptide is not higher than 10 wt%.
5. The jellyfish polypeptide of claim 2, wherein the substrate comprises glycine; the glycine content is 10-15 wt%.
6. The use of jellyfish polypeptides according to any one of claims 1 to 5 in the preparation of skin care products.
7. The use of jellyfish polypeptides according to claim 6, wherein the skin care preparation is prepared by a method comprising the steps of: preparing the jellyfish polypeptide into an aqueous solution with the concentration of 0.02-10mg/mL by using deionized water, and then filtering the aqueous solution by using a microporous filter membrane with the pore diameter of not more than 0.25 mu m.
8. The use of jellyfish polypeptides according to claim 7 wherein the skin care product is an inflammatory factor inhibitor.
9. Use of jellyfish polypeptides according to claim 7 wherein the skin care product is a skin barrier repair agent.
10. The use of jellyfish polypeptide according to claim 7 wherein the skin care product is an agent that promotes collagen type I synthesis in skin cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110381493.8A CN113318003A (en) | 2021-04-08 | 2021-04-08 | Jellyfish polypeptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110381493.8A CN113318003A (en) | 2021-04-08 | 2021-04-08 | Jellyfish polypeptide and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113318003A true CN113318003A (en) | 2021-08-31 |
Family
ID=77414664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110381493.8A Pending CN113318003A (en) | 2021-04-08 | 2021-04-08 | Jellyfish polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113318003A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114438157A (en) * | 2022-03-28 | 2022-05-06 | 中国科学院海洋研究所 | Jellyfish peptide for whitening as well as preparation method and application thereof |
| CN115177557A (en) * | 2021-09-07 | 2022-10-14 | 海臻(上海)生物科技有限公司 | Jellyfish moisturizing and relieving mask liquid composition and product thereof |
| CN115192486A (en) * | 2021-09-07 | 2022-10-18 | 海臻(上海)生物科技有限公司 | Jellyfish nourishing anti-aging mask liquid composition and product thereof |
| CN115177557B (en) * | 2021-09-07 | 2024-06-28 | 海臻(上海)生物科技有限公司 | Jellyfish moisturizing and soothing mask liquid composition and product thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101302251A (en) * | 2008-05-20 | 2008-11-12 | 张丽丽 | Cyanea-originated glucoprotein having immunopotentiation activity, preparation and use thereof |
| CN101353380A (en) * | 2008-05-20 | 2009-01-28 | 张丽丽 | Jellyfish origin immune activity enhanced collagen peptide, preparation and use thereof |
| CN103819552A (en) * | 2014-02-17 | 2014-05-28 | 中国人民解放军第二军医大学 | Cyanea capillata polypeptide growth factor, preparation method and applications thereof |
| CN108456248A (en) * | 2017-02-22 | 2018-08-28 | 阿罕默德阿克亚里 | Hydrolyze jellyfish I types, II types and collagen type v albumen and application thereof |
| CN109875910A (en) * | 2019-04-19 | 2019-06-14 | 武汉百思凯瑞生物科技有限公司 | A kind of complex polypeptide nano vesicle and its preparation method and application with skin repair function |
| CN111011575A (en) * | 2019-12-30 | 2020-04-17 | 广州市科能化妆品科研有限公司 | Jellyfish growth promoting peptide and preparation method thereof |
| CN111393521A (en) * | 2020-03-20 | 2020-07-10 | 张培华 | Extraction method of jellyfish collagen |
-
2021
- 2021-04-08 CN CN202110381493.8A patent/CN113318003A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101302251A (en) * | 2008-05-20 | 2008-11-12 | 张丽丽 | Cyanea-originated glucoprotein having immunopotentiation activity, preparation and use thereof |
| CN101353380A (en) * | 2008-05-20 | 2009-01-28 | 张丽丽 | Jellyfish origin immune activity enhanced collagen peptide, preparation and use thereof |
| CN103819552A (en) * | 2014-02-17 | 2014-05-28 | 中国人民解放军第二军医大学 | Cyanea capillata polypeptide growth factor, preparation method and applications thereof |
| CN108456248A (en) * | 2017-02-22 | 2018-08-28 | 阿罕默德阿克亚里 | Hydrolyze jellyfish I types, II types and collagen type v albumen and application thereof |
| CN109875910A (en) * | 2019-04-19 | 2019-06-14 | 武汉百思凯瑞生物科技有限公司 | A kind of complex polypeptide nano vesicle and its preparation method and application with skin repair function |
| CN111011575A (en) * | 2019-12-30 | 2020-04-17 | 广州市科能化妆品科研有限公司 | Jellyfish growth promoting peptide and preparation method thereof |
| CN111393521A (en) * | 2020-03-20 | 2020-07-10 | 张培华 | Extraction method of jellyfish collagen |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115177557A (en) * | 2021-09-07 | 2022-10-14 | 海臻(上海)生物科技有限公司 | Jellyfish moisturizing and relieving mask liquid composition and product thereof |
| CN115192486A (en) * | 2021-09-07 | 2022-10-18 | 海臻(上海)生物科技有限公司 | Jellyfish nourishing anti-aging mask liquid composition and product thereof |
| CN115177557B (en) * | 2021-09-07 | 2024-06-28 | 海臻(上海)生物科技有限公司 | Jellyfish moisturizing and soothing mask liquid composition and product thereof |
| CN114438157A (en) * | 2022-03-28 | 2022-05-06 | 中国科学院海洋研究所 | Jellyfish peptide for whitening as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113318003A (en) | Jellyfish polypeptide and application thereof | |
| KR102007762B1 (en) | Composition for skin and fur of companion animal | |
| CN102421412B (en) | Composition containing chamaecyparis obtusa polysaccharides to be externally applied to skin | |
| KR20150120426A (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
| JP2018538256A (en) | PALMARIA Synergistic extract of PALMATA and jasmine, compositions containing it and their use | |
| CN108852951B (en) | Skin moistening and cleaning composition and plant shower gel | |
| CN114317661B (en) | Method for preparing multiple active collagen | |
| CN108815094A (en) | A kind of purposes of extracellular matrix freeze-dried powder | |
| CN114423400B (en) | Cosmetic composition containing graphene quantum dots as active ingredient | |
| CN110664995A (en) | Composition containing recombinant human fibronectin peptide | |
| ES2398809B1 (en) | PRODUCT FOR THE PREPARATION OF DERMATOLOGICAL, COSMETIC OR COSMECEUTIC COMPOSITIONS INTENDED FOR SKIN TREATMENT. | |
| KR101099665B1 (en) | A cosmetic composition comprising the aplysia kurodai extract for skin moisturizing effect and improving skin wrinkles | |
| CN113855597A (en) | Antioxidant, anti-inflammatory and soothing repair composition, preparation method and application thereof | |
| CN114053164A (en) | Essence with anti-inflammatory, acne-removing and skin regeneration and repair promoting functions and preparation method thereof | |
| CN110684713B (en) | Construction method of in-vitro recombinant epidermis model for diaper dermatitis | |
| WO2021017255A1 (en) | Protein peptide moisturizing liquid dissolved in weak alkaline water and preparation method therefor | |
| CN108812639A (en) | A kind of extracellular matrix freeze-dried powder | |
| CN113768822B (en) | Application of hedysarum polybasic polysaccharide in preparation of cosmetics with moisture absorption, moisturizing or relieving effects | |
| TW202008997A (en) | Topical composition, medicinal composition containing inactivated culture and use thereof for facilitating wound healing and scar reduction | |
| KR20190115298A (en) | Composition of skin external application for promoting skin volume or renewing | |
| CN113476362B (en) | Facial skin cutin renewal promoter and application thereof | |
| CN115261309B (en) | Method for promoting cell proliferation and cosmetic or pharmaceutical comprising cytokine | |
| CN113398055B (en) | Silkworm excrement extract, preparation method thereof and application thereof in cosmetics | |
| CN110327273B (en) | Whitening composition, whitening skin care product and preparation method thereof | |
| KR102109829B1 (en) | Cosmetic Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |